GlassScriptPhysician profile
Steven D Shapiro
NPI 1720043466
$9,739.26
in general payments reported to CMS, 2019-2025
40 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $381 · 2021: $1,818 · 2022: $1,581 · 2023: $1,552 · 2024: $1,471 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,525.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,484.38 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Galderma Laboratories, L.P. | $715.10 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $492.35 | 2019-2025 | Winlevi, Absorica Ld |
| Revance Therapeutics, INC. | $466.56 | 2024-2025 | Daxi, Daxxify |
| Incyte Corporation | $421.40 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $418.02 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $408.22 | 2019-2024 | Arazlo, Cabtreo, Jublia |
| Amgen INC. | $379.50 | 2020-2024 | Otezla |
| Dermavant Sciences, INC. | $351.67 | 2023-2024 | Vtama |
| Lnhc, INC | $327.50 | 2025 | Zelsuvmi |
| Regeneron Healthcare Solutions, INC. | $295.56 | 2019-2024 | Dupixent |
| Genzyme Corporation | $273.87 | 2019-2023 | |
| Ucb, INC. | $242.65 | 2019-2025 | Bimzelx |
| Almirall LLC | $237.12 | 2019-2023 | Seysara |
| Organon LLC | $217.24 | 2025 | Vtama |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.61 | 2022-2025 | Spevigo |
| Leo Pharma INC. | $204.84 | 2019-2025 | Adbry |
| Mayne Pharma Commercial LLC | $180.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $164.24 | 2019-2025 | |
| Janssen Biotech, INC. | $154.67 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $148.13 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $129.43 | 2023-2025 | Zoryve |
| Prugen, INC. Pharmaceuticals | $123.39 | 2019 | |
| Lilly USA, LLC | $120.81 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Biofrontera INC. | $72.21 | 2019-2025 | Ameluz |
| Organogenesis INC. | $62.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.49 | 2022-2025 | Sotyktu |
| Encore Dermatology INC. | $56.83 | 2019 | |
| Kerecis Limited | $50.22 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Biocon Biologics INC | $40.53 | 2025 | Yesintek |
| Strata Skin Sciences, INC. | $36.20 | 2019-2023 | Xtrac |
| Botanix Sb INC | $32.79 | 2025 | Sofdra |
| Boston Scientific Corporation | $30.42 | 2023 | |
| Allergan, INC. | $23.62 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.31 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $18.69 | 2019 | |
| Blueprint Medicines Corporation | $18.17 | 2024 | Ayvakit |
| Merz North America, INC. | $17.26 | 2021 | |
| Mylan Pharmaceuticals INC. | $17.11 | 2019 | |
| Verrica Pharmaceuticals INC. | $13.66 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.